Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1919786
PUBLISHER: BCC Research | PRODUCT CODE: 1919786
Oligonucleotides: Global Markets
PUBLISHED:
PAGES: 125 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global market for oligonucleotides was valued at $9.1 billion in 2025 and is estimated to reach $15.7 billion by 2030, at a compound annual growth rate (CAGR) of 11.5% from 2025 through 2030.
The North American market for oligonucleotides was valued at $3.7 billion in 2025 and is estimated to reach $6.3 billion by 2030, at a CAGR of 11.3% from 2025 through 2030.
The Asia-Pacific market for oligonucleotides was valued at $2.2 billion in 2025 and is estimated to reach $4 billion by 2030, at a CAGR of 13.3% from 2025 through 2030.
Report Scope
The report provides an overview of the oligonucleotides market and analyzes market trends. It includes global revenue ($ Million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented by product type, application and region.
By product type, the market is segmented into oligonucleotide drugs, synthesized oligos, equipment and reagents, and services. The application segment is characterized by research and therapeutics and diagnostics. The report also includes an overview of the regulatory landscape for oligonucleotides.
The report also focuses on the regional segmentation of the market. The regions covered in this study include North America, Europe, the Asia-Pacific and the rest of the world (RoW), with a focus on major countries in these regions.
The report focuses on the major driving trends and challenges affecting the market and vendor landscape. It analyzes environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report concludes with an analysis of the competitive landscape and industry structure. It also includes a dedicated section of company profiles, detailing leading market companies.
Report Includes
- 64 data tables and 55 additional tables
- In-depth analysis of the global oligonucleotides market
- Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects for the global oligonucleotide synthesis market, accompanied by a market share analysis by product, application and region
- Facts and figures pertaining to the global market dynamics, opportunities and deterrents, technological advancements, regulations, prospects and the impact of macroeconomic factors
- Insights derived from Porter's Five Forces model, as well as global supply chain analyses
- Patent review, featuring key granted and published patents
- Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Company profiles of major players within the industry, including Alnylam Pharmaceuticals Inc., Biogen/Ionis Pharmaceuticals Inc., Novartis AG, and Sarepta Therapeutics Inc.
Product Code: BIO220C
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics and Growth Factors
- Emerging Technologies
- Segmental Analysis
- Regional Analysis
- Conclusion
Chapter 2 Market Overview
- Overview
- Types of Oligonucleotides
- Mechanisms of Action of Oligonucleotides
- Oligonucleotide Synthesis Processes
- Solid Phase Chemical Synthesis
- Porter's Five Forces Analysis in the Global Oligonucleotides Market
- Macroeconomic Factor Analysis
- Impact of the U.S. Tariffs
- Growing Rare Disease Funding
- Geopolitical Factors
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Growing Focus on Personalized Medicine
- Increasing Use of Synthesized Oligos in Therapeutic Applications
- Rising Prevalence of Rare Diseases
- Market Restraints/Challenges
- Product Withdrawals and Clinical Trial Failures
- Complexities Associated with Oligos Manufacturing
- High Treatment Costs of Oligonucleotide Therapeutics
- Market Opportunities
- Expanding Application Areas of Oligonucleotides
- Expansion of Companies
- DNA Nanotechnology for Drug Delivery
Chapter 4 Regulatory Landscape
- Regulatory Paths for Oligonucleotide Therapeutics
- U.S.
- European Union
- Asia-Pacific
Chapter 5 Emerging Technologies
- Key Takeaways
- Emerging Technologies
- Enzymatic Oligonucleotide Synthesis
- Advances in RNAi Delivery Systems
- Circulating miRNA Diagnostics for Noninvasive Health Monitoring
- Innovative Oligonucleotide Conjugation Methods
- Pipeline Analysis
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Market Analysis by Product Type
- Key Takeaways
- Oligonucleotide Drugs
- Synthesized Oligos
- Equipment and Reagents
- Services
- Market Analysis by Application
- Key Takeaways
- Diagnostics and Therapeutics
- Research
- Geographic Breakdown
- Market Analysis by Region
- Key Takeaways
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Competitive Intelligence
- Key Takeaways
- Industry Structure
- Company Share Analysis of the Global Oligonucleotides Market
- Strategic Analysis
- Funding Outlook
Chapter 8 Sustainability in the Global Oligonucleotides Market: An ESG Perspective
- Introduction to ESG
- ESG Risk Ratings
- Conclusion
Chapter 9 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- AGILENT TECHNOLOGIES INC.
- AJINOMOTO BIO-PHARMA
- ALNYLAM PHARMACEUTICALS INC.
- ASTELLAS PHARMA INC.
- BIOGEN
- CHARLES RIVER LABORATORIES
- EUROFINS GENOMICS
- GENSCRIPT
- INTEGRATED DNA TECHNOLOGIES INC.
- MERCK KGAA
- NOVARTIS AG
- NOVO NORDISK A/S
- REVVITY
- SAREPTA THERAPEUTICS INC.
- THERMO FISHER SCIENTIFIC INC.
- Emerging Startups/Market Disruptors
Product Code: BIO220C
List of Tables
- Summary Table : Global Market for Oligonucleotides, by Region, Through 2030
- Table 1 : FDA-Approved ASOs
- Table 2 : RNAi-Approved Drug List
- Table 3 : List of Approved Oligonucleotide Therapeutics, 2025
- Table 4 : List of Selected Pipeline Oligonucleotide Molecules
- Table 5 : Global Market for Oligonucleotides, by Product Type, Through 2030
- Table 6 : Global Market for Oligonucleotide Drugs, by Region, Through 2030
- Table 7 : Global Market for Synthesized Oligos, by Region, Through 2030
- Table 8 : Global Market for Oligonucleotide Equipment and Reagents, by Region, Through 2030
- Table 9 : Global Market for Oligonucleotide Services, by Region, Through 2030
- Table 10 : Global Market for Oligonucleotide, by Application, Through 2030
- Table 11 : Global Market for Oligonucleotides for Diagnostic and Therapeutics, by Region, Through 2030
- Table 12 : Global Market for Oligonucleotides for Research, by Region, Through 2030
- Table 13 : Global Market for Oligonucleotides, by Region, Through 2030
- Table 14 : North American Market for Oligonucleotides, by Country, Through 2030
- Table 15 : North American Market for Oligonucleotides, by Product Type, Through 2030
- Table 16 : North American Market for Oligonucleotides, by Application, Through 2030
- Table 17 : U.S. Market for Oligonucleotides, by Product Type, Through 2030
- Table 18 : U.S. Market for Oligonucleotides, by Application, Through 2030
- Table 19 : Canadian Market for Oligonucleotides, by Product Type, Through 2030
- Table 20 : Canadian Market for Oligonucleotides, by Application, Through 2030
- Table 21 : Mexican Market for Oligonucleotides, by Product Type, Through 2030
- Table 22 : Mexican Market for Oligonucleotides, by Application, Through 2030
- Table 23 : European Market for Oligonucleotides, by Country, Through 2030
- Table 24 : European Market for Oligonucleotides, by Product Type, Through 2030
- Table 25 : European Market for Oligonucleotides, by Application, Through 2030
- Table 26 : German Market for Oligonucleotides, by Product Type, Through 2030
- Table 27 : German Market for Oligonucleotides, by Application, Through 2030
- Table 28 : U.K. Market for Oligonucleotides, by Product Type, Through 2030
- Table 29 : U.K. Market for Oligonucleotides, by Application, Through 2030
- Table 30 : French Market for Oligonucleotides, by Product Type, Through 2030
- Table 31 : French Market for Oligonucleotides, by Application, Through 2030
- Table 32 : Italian Market for Oligonucleotides, by Product Type, Through 2030
- Table 33 : Italian Market for Oligonucleotides, by Application, Through 2030
- Table 34 : Spanish Market for Oligonucleotides, by Product Type, Through 2030
- Table 35 : Spanish Market for Oligonucleotides, by Application, Through 2030
- Table 36 : Rest of Europe Market for Oligonucleotides, by Product Type, Through 2030
- Table 37 : Rest of Europe Market for Oligonucleotides, by Application, Through 2030
- Table 38 : Asia-Pacific Market for Oligonucleotides, by Country, Through 2030
- Table 39 : Asia-Pacific Market for Oligonucleotides, by Product Type, Through 2030
- Table 40 : Asia-Pacific Market for Oligonucleotides, by Application, Through 2030
- Table 41 : Chinese Market for Oligonucleotides, by Product Type, Through 2030
- Table 42 : Chinese Market for Oligonucleotides, by Application, Through 2030
- Table 43 : Japanese Market for Oligonucleotides, by Product Type, Through 2030
- Table 44 : Japanese Market for Oligonucleotides, by Application, Through 2030
- Table 45 : South Korean Market for Oligonucleotides, by Product Type, Through 2030
- Table 46 : South Korean Market for Oligonucleotides, by Application, Through 2030
- Table 47 : Indian Market for Oligonucleotides, by Product Type, Through 2030
- Table 48 : Indian Market for Oligonucleotides, by Application, Through 2030
- Table 49 : Australian Market for Oligonucleotides, by Product Type, Through 2030
- Table 50 : Australian Market for Oligonucleotides, by Application, Through 2030
- Table 51 : Rest of Asia-Pacific Market for Oligonucleotides, by Product Type, Through 2030
- Table 52 : Rest of Asia-Pacific Market for Oligonucleotides, by Application, Through 2030
- Table 53 : RoW Market for Oligonucleotides, by Subregion, Through 2030
- Table 54 : RoW Market for Oligonucleotides, by Product Type, Through 2030
- Table 55 : RoW Market for Oligonucleotides, by Application, Through 2030
- Table 56 : Recent Developments in the Global Oligonucleotides Market, 2022-2025
- Table 57 : Key Investment Deals in the Oligonucleotides Industry, 2024 and 2025
- Table 58 : Key Focus Areas in ESG Metrics
- Table 59 : ESG Risk Rankings for Oligonucleotide Companies, 2025
- Table 60 : Report Information Sources
- Table 61 : Abbreviations Used in the Global Oligonucleotides Market
- Table 62 : Agilent Technologies Inc.: Company Snapshot
- Table 63 : Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024
- Table 64 : Agilent Technologies Inc.: Product Portfolio
- Table 65 : Agilent Technologies Inc.: News/Key Developments, 2024
- Table 66 : Ajinomoto Bio-Pharma: Company Snapshot
- Table 67 : Ajinomoto Bio-Pharma: Product Portfolio
- Table 68 : Ajinomoto Bio-Pharma: News/Key Developments, 2025
- Table 69 : Alnylam Pharmaceuticals Inc.: Company Snapshot
- Table 70 : Alnylam Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
- Table 71 : Alnylam Pharmaceuticals Inc.: Product Portfolio
- Table 72 : Alnylam Pharmaceuticals Inc.: News/Key Developments, 2022-2025
- Table 73 : Astellas Pharma Inc.: Company Snapshot
- Table 74 : Astellas Pharma Inc.: Financial Performance, FY 2023 and 2024
- Table 75 : Astellas Pharma Inc.: Product Portfolio
- Table 76 : Astellas Pharma Inc.: News/Key Developments, 2023
- Table 77 : Biogen: Company Snapshot
- Table 78 : Biogen: Financial Performance, FY 2023 and 2024
- Table 79 : Biogen: Product Portfolio
- Table 80 : Biogen: News/Recent Developments, 2022-2025
- Table 81 : Charles River Laboratories: Company Snapshot
- Table 82 : Charles River Laboratories: Financial Performance, FY 2023 and 2024
- Table 83 : Charles River Laboratories: Product Portfolio
- Table 84 : Charles River Laboratories: News/Key Developments, 2023
- Table 85 : Eurofins Genomics: Company Snapshot
- Table 86 : Eurofins Genomics: Product Portfolio
- Table 87 : Eurofins Genomics: News/Key Developments, 2024
- Table 88 : GenScript: Company Snapshot
- Table 89 : GenScript: Financial Performance, FY 2023 and 2024
- Table 90 : GenScript: Product Portfolio
- Table 91 : GenScript: News/Key Developments, 2025
- Table 92 : Integrated DNA Technologies Inc.: Company Snapshot
- Table 93 : Integrated DNA Technologies Inc.: Product Portfolio
- Table 94 : Integrated DNA Technologies Inc.: News/Key Developments, 2023
- Table 95 : Merck KGaA: Company Snapshot
- Table 96 : Merck KGaA: Financial Performance, FY 2023 and 2024
- Table 97 : Merck KGaA: Product Portfolio
- Table 98 : Merck KGaA: News/Key Developments, 2025
- Table 99 : Novartis AG: Company Snapshot
- Table 100 : Novartis AG: Financial Performance, FY 2023 and 2024
- Table 101 : Novartis AG: Product Portfolio
- Table 102 : Novartis AG: News/Key Developments, 2023-2025
- Table 103 : Novo Nordisk A/S: Company Snapshot
- Table 104 : Novo Nordisk A/S: Financial Performance, FY 2023 and 2024
- Table 105 : Novo Nordisk A/S: Product Portfolio
- Table 106 : Novo Nordisk A/S: News/Key Developments, 2023
- Table 107 : Revvity: Company Snapshot
- Table 108 : Revvity: Financial Performance, FY 2023 and 2024
- Table 109 : Revvity: Product Portfolio
- Table 110 : Sarepta Therapeutics Inc.: Company Snapshot
- Table 111 : Sarepta Therapeutics Inc.: Financial Performance, FY 2023 and 2024
- Table 112 : Sarepta Therapeutics Inc.: Product Portfolio
- Table 113 : Sarepta Therapeutics Inc.: News/Key Developments, 2024
- Table 114 : Thermo Fisher Scientific Inc.: Company Snapshot
- Table 115 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
- Table 116 : Thermo Fisher Scientific Inc.: Product Portfolio
- Table 117 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023 and 2024
- Table 118 : List of a Few Emerging Startups
List of Figures
- Summary Figure : Global Market Shares for Oligonucleotides, by Region, 2024
- Figure 1 : Porter's Five Forces Analysis: Global Oligonucleotides Market
- Figure 2 : Market Dynamics of Oligonucleotides
- Figure 3 : Emerging Technologies in the Oligonucleotides Market
- Figure 4 : Global Market Shares for Oligonucleotides, by Product Type, 2024
- Figure 5 : Global Market Shares for Oligonucleotides, by Application, 2024
- Figure 6 : Global Market Shares for Oligonucleotides, by Region, 2024
- Figure 7 : North American Market Shares for Oligonucleotides, by Country, 2024
- Figure 8 : European Market Shares for Oligonucleotides, by Country, 2024
- Figure 9 : Asia-Pacific Market Shares for Oligonucleotides, by Country, 2024
- Figure 10 : RoW Market Shares for Oligonucleotides, by Subregion, 2024
- Figure 11 : Global Market Shares for Oligonucleotides, by Company, 2024
- Figure 12 : Agilent Technologies Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 13 : Agilent Technologies Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 14 : Alnylam Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 15 : Astellas Pharma Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 16 : BIOGEN: Revenue Shares, by Country/Region, FY 2024
- Figure 17 : Charles River Laboratories: Revenue Shares, by Business Unit, FY 2024
- Figure 18 : Charles River Laboratories: Revenue Shares, by Country/Region, FY 2024
- Figure 19 : GENSCRIPT: Revenue Shares, by Business Unit, FY 2024
- Figure 20 : GENSCRIPT: Revenue Shares, by Country/Region, FY 2024
- Figure 21 : Merck KGaA: Revenue Shares, by Business Unit, FY 2024
- Figure 22 : Merck KGaA: Revenue Shares, by Country/Region, FY 2024
- Figure 23 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
- Figure 24 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
- Figure 25 : Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2024
- Figure 26 : Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2024
- Figure 27 : REVVITY: Revenue Shares, by Business Unit, FY 2024
- Figure 28 : REVVITY: Revenue Shares, by Country/Region, FY 2024
- Figure 29 : Sarepta Therapeutics Inc.: Revenue Shares, by Country/Region, FY 2024
- Figure 30 : Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2024
- Figure 31 : Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2024
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.